MA35351B1 - Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. - Google Patents

Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.

Info

Publication number
MA35351B1
MA35351B1 MA36755A MA36755A MA35351B1 MA 35351 B1 MA35351 B1 MA 35351B1 MA 36755 A MA36755 A MA 36755A MA 36755 A MA36755 A MA 36755A MA 35351 B1 MA35351 B1 MA 35351B1
Authority
MA
Morocco
Prior art keywords
diabetes
novel
treatment
derivative useful
tetrahydroquinoline derivative
Prior art date
Application number
MA36755A
Other languages
English (en)
French (fr)
Inventor
Chafiq Hamdouchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35351(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA35351B1 publication Critical patent/MA35351B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA36755A 2011-08-17 2014-02-13 Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. MA35351B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524462P 2011-08-17 2011-08-17
PCT/US2012/050051 WO2013025424A1 (en) 2011-08-17 2012-08-09 A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes

Publications (1)

Publication Number Publication Date
MA35351B1 true MA35351B1 (fr) 2014-08-01

Family

ID=46690732

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36755A MA35351B1 (fr) 2011-08-17 2014-02-13 Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.

Country Status (30)

Country Link
US (1) US8431706B2 (https=)
EP (1) EP2744806B1 (https=)
JP (1) JP5903162B2 (https=)
KR (1) KR101570624B1 (https=)
CN (1) CN103687856B (https=)
AP (1) AP3589A (https=)
AR (1) AR087451A1 (https=)
AU (1) AU2012295372A1 (https=)
BR (1) BR112014003079A2 (https=)
CA (1) CA2843474C (https=)
CL (1) CL2014000357A1 (https=)
CO (1) CO6880069A2 (https=)
CR (1) CR20140052A (https=)
DO (1) DOP2014000018A (https=)
EA (1) EA022165B1 (https=)
EC (1) ECSP14013211A (https=)
ES (1) ES2578165T3 (https=)
GT (1) GT201400022A (https=)
IL (1) IL230635A (https=)
IN (1) IN2014MN00191A (https=)
MA (1) MA35351B1 (https=)
MX (1) MX2014001832A (https=)
PE (1) PE20140831A1 (https=)
PH (1) PH12014500366A1 (https=)
SG (1) SG11201401793PA (https=)
TN (1) TN2014000058A1 (https=)
TW (1) TWI537262B (https=)
UA (1) UA110983C2 (https=)
WO (1) WO2013025424A1 (https=)
ZA (1) ZA201400705B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2013MU03577A (https=) 2013-11-14 2015-07-31 Cadila Healthcare Ltd
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
US11964938B2 (en) 2018-01-08 2024-04-23 Celon Pharma S.A. 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US12516036B2 (en) 2019-05-31 2026-01-06 Hyundai Pharm Co., Ltd. Crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
WO2021083270A1 (zh) * 2019-10-31 2021-05-06 中国石油化工股份有限公司 负载型催化剂及其制备方法和应用
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도
CN115317484B (zh) * 2022-08-26 2023-07-18 北京箭牧科技有限公司 Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
NZ527276A (en) * 2001-03-27 2004-11-26 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists
JP5299810B2 (ja) * 2004-02-27 2013-09-25 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法
US7786165B2 (en) * 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) * 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
CA2843474C (en) 2015-12-15
JP2014521744A (ja) 2014-08-28
PE20140831A1 (es) 2014-07-14
MX2014001832A (es) 2014-02-27
WO2013025424A1 (en) 2013-02-21
ES2578165T3 (es) 2016-07-21
DOP2014000018A (es) 2014-04-15
ECSP14013211A (es) 2014-03-31
TN2014000058A1 (en) 2015-07-01
CO6880069A2 (es) 2014-02-28
CA2843474A1 (en) 2013-02-21
EP2744806A1 (en) 2014-06-25
AP3589A (en) 2016-02-15
UA110983C2 (uk) 2016-03-10
IN2014MN00191A (https=) 2015-08-21
GT201400022A (es) 2015-01-16
CN103687856B (zh) 2015-07-22
EA022165B1 (ru) 2015-11-30
CL2014000357A1 (es) 2014-09-05
JP5903162B2 (ja) 2016-04-13
KR101570624B1 (ko) 2015-11-19
BR112014003079A2 (pt) 2017-02-21
TW201319060A (zh) 2013-05-16
US20130045990A1 (en) 2013-02-21
NZ621248A (en) 2015-08-28
IL230635A (en) 2015-11-30
EA201490269A1 (ru) 2014-05-30
TWI537262B (zh) 2016-06-11
CR20140052A (es) 2014-06-20
AR087451A1 (es) 2014-03-26
PH12014500366A1 (en) 2014-04-14
AP2014007436A0 (en) 2014-02-28
IL230635A0 (en) 2014-03-31
ZA201400705B (en) 2015-11-25
CN103687856A (zh) 2014-03-26
SG11201401793PA (en) 2014-09-26
EP2744806B1 (en) 2016-04-27
US8431706B2 (en) 2013-04-30
AU2012295372A1 (en) 2014-01-23
KR20140041835A (ko) 2014-04-04

Similar Documents

Publication Publication Date Title
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
MA33840B1 (fr) Nouveau composé de spiropipéridine
JOP20210064A1 (ar) عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة
MA35432B1 (fr) Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
MA33662B1 (fr) Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
MA34965B1 (fr) Procédé de production de dérivé de dihydrobenzofurane optiquement actif
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
IN2014MN02106A (https=)
MA37888B1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
MA38333A1 (fr) Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
MA38227B1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA37405A1 (fr) Composés hétérocyclyle
MA39048B1 (fr) Nouveaux inhibiteurs de la dgat2
MA40895B1 (fr) Synthèse de copanlisib et son sel de dichlorhydrate
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
JOP20130213B1 (ar) معارضات لمستقبلht3-5
IN2014MN01521A (https=)
TN2012000620A1 (fr) Procede de preparation du sel de l-arginine du perindopril